U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860347) titled 'Biomarkers for Fatigue in Patients with Myasthenia Gravis' on Aug. 03, 2022.
Brief Summary: Rationale: Myasthenia Gravis (MG) is a chronic autoimmune disease affecting the neuromuscular junction. Although a hallmark of MG is muscle fatigability due to dysfunction of the neuromuscular junction (peripheral fatigue), a large number of MG patients also report symptoms of central or cognitive fatigue. Central fatigue is defined as an experienced lack of energy, physically and/or mentally. In October 2019 we performed a cross-sectional survey study (P15.287) among 420 Dutch MG patients showing a clinically relevant central fatigue rate of...